FDA-approved Wegovy should match official labeling and approved distribution pathways
Ok while nursing though 6.27.19 Agnieszka Saba said: Im actually confused
A 2023 systematic review noted that gastrointestinal side effects like constipation, nausea, and diarrhoea were more prevalent during the dose-escalation phase of tirzepatide, particularly in individuals who had pre-existing digestive sensitivities
Consequently, no dose adjustment is recommended for hepatic impairment, though clinical experience in patients with severe hepatic disease remains limited
Hackam DG, Peterson JC, and Spence JD (2000)
A multivariate regression informs driver elasticities before ARIMA smoothing projects values through 2030, while scenario analysis tests high and low uptake cases